论文部分内容阅读
目的探讨低分子量肝素钙治疗对慢性阻塞性肺疾病急性加重期(acute exacerbations of chronic obstructive pulmonary disease,AECOPD)患者肺功能和凝血功能的影响。方法根据入选标准,随机选取2010-08/2013-08月在作者医院确诊并接受治疗的慢性阻塞性肺疾病急性加重期患者84例作为研究对象,按照随机数字表法随机分为抗凝组和对照组,各42例。对照组患者采取常规治疗;抗凝组给予低分子肝素5000 U,腹部皮下注射1/d,10天为一个疗程。结果治疗后抗凝组患者的动脉血气指标改善程度均显著优于对照组(P<0.05);治疗后抗凝组患者的血粘度指标(高切粘度和低切粘度)改善程度均显著优于对照组患者(P<0.05);抗凝组患者治疗后的肺功能指标(FEV1和FEV1/FVC)改善程度均显著高于对照组(P<0.05);抗凝组患者治疗后的呼吸困难Borg评分改善程度显著优于对照组患者(t=7.612,P<0.05)。抗凝组与对照组患者住院时间的比较明显缩短(P<0.05);治疗后抗凝组患者的凝血功能指标改善程度均显著优于对照组患者(P<0.05)。结论低分子量肝素能有效改善AECOPD患者血黏度、肺功能、凝血功能、动脉血气指标、呼吸困难指数改善明显,减少住院时间显著,使用安全方便,值得临床推广。
Objective To investigate the effects of low molecular weight heparin calcium treatment on pulmonary function and coagulation function in patients with acute exacerbations of chronic obstructive pulmonary disease (AECOPD). Methods According to the inclusion criteria, 84 patients with acute exacerbation of chronic obstructive pulmonary disease diagnosed and treated in our hospital from 2010-08 / 2013-08 were randomly selected as the research object, randomly divided into anticoagulation group Control group, each 42 cases. Control group of patients taking conventional treatment; anticoagulant group given low molecular weight heparin 5000 U, abdominal subcutaneous injection 1 / d, 10 days for a course of treatment. Results After treatment, the improvement of arterial blood gas index in patients with anticoagulation was significantly better than that of the control group (P <0.05). After treatment, the improvement of blood viscosity index (high and low shear viscosity) in the anticoagulation group was significantly better than that of the control group (P <0.05). The improvement of lung function indexes (FEV1 and FEV1 / FVC) after treatment in the anticoagulant group was significantly higher than that in the control group (P <0.05). After treatment, the patients with anticoagulant dyspnea Borg The score improved significantly better than the control group (t = 7.612, P <0.05). The hospitalization time of patients in anticoagulation group and control group was significantly shorter than that in control group (P <0.05). After treatment, the improvement of coagulation function in patients with anticoagulation was significantly better than that in control group (P <0.05). Conclusion Low molecular weight heparin can effectively improve the blood viscosity, pulmonary function, coagulation function, arterial blood gas index and respiratory dysfunction index of AECOPD patients. It can significantly reduce the hospitalization time, and is safe and convenient to use. It is worthy of clinical promotion.